title: Baseline polyp size as a potential predictive factor for recurrence of polypoidal choroidal vasculopathy.
abstract: OBJECTIVE
  To investigate the predictive factors for recurrence of polypoidal choroidal vasculopathy (PCV).
  
  
  METHODS
  The medical records of 78 consecutive patients (78 eyes) with treatment-naïve PCV who responded to first-line treatment and completed at least a 3-year follow-up after the first remission were retrospectively analyzed. In this comparative cohort study, baseline characteristics were compared between the patients who had at least one recurrence (the recurrence group) and those without recurrence (the non-recurrence group) during at least 3-year follow-up periods. In addition, possible predictive factors for recurrence of PCV were investigated by using Cox regression analysis.
  
  
  RESULTS
  Within 3 years of the first remission, 50 eyes (64 %) showed at least one recurrence (mean 1.5; 1 to ∼2 times). There were no significant differences in the baseline characteristics between the recurrence group and the non-recurrence group. However, the largest polyp diameter was significantly different: the mean largest polyp diameter (524 ± 340 μm) was significantly larger in the recurrence group compared to that of the non-recurrence group (352 ± 173 μm; P = 0.038). Cox regression analysis showed that the largest polyp diameter at baseline significantly correlated with recurrence of PCV (B = 1.470, P = 0.015).
  
  
  CONCLUSIONS
  The largest polyp diameter at baseline may be predictive for PCV recurrence, as it was significantly larger in patients who had at least one recurrence.
authors.affiliation: Institute of Vision Research, Department of Ophthalmology, Severance Hospital, Yonsei University College of Medicine, Seoul, 120-752, Republic of Korea.|Department of Ophthalmology, Catholic Kwandong Universtiy College of Medicine, International St. Mary's Hospital, Incheon, Republic of Korea.
authors.forename: Hae Min
authors.initials: HM
authors.lastname: Kang
authors.affiliation: Institute of Vision Research, Department of Ophthalmology, Severance Hospital, Yonsei University College of Medicine, Seoul, 120-752, Republic of Korea.
authors.forename: Hyoung Jun
authors.initials: HJ
authors.lastname: Koh
authors.affiliation: Institute of Vision Research, Department of Ophthalmology, Severance Hospital, Yonsei University College of Medicine, Seoul, 120-752, Republic of Korea. sunglee@yuhs.ac.
authors.forename: Sung Chul
authors.initials: SC
authors.lastname: Lee
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D002829:Choroid / Q000000981:diagnostic imaging*; D015862:Choroid Diseases / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008297:Male; D010778:Photochemotherapy / Q000379:methods*; D011127:Polyps / Q000175:diagnosis / Q000188:drug therapy*; D011379:Prognosis; D000069579:Ranibizumab / Q000008:administration & dosage*; D012008:Recurrence; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab
keywords: Anti-vascular endothelial growth factor therapy; Photodynamic therapy; Polypoidal choroidal vasculopathy; Recurrence